Hi-jiang (john) Lu

Biography

 Shi-Jiang (John) Lu is currently the President and CEO of VCANBIO Center for Translational Biotechnology Corp. and HebeCell Corporation, two newly formed companies focused on the development and clinical translation of regenerative medicine and cell therapy technologies. Before joining VCANBIO Center for Translational Biotechnology and HebeCell, John was the Senior Director of Research at Ocata Therapeutics, which was recently acquired by Astellas, the 2nd largest pharmaceutical company of Japan. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. John has been conducting translational researches and discovery of novel therapeutic strategies utilizing human embryonic stem cells (hESC), induced pluripotent stem cells (iPSC) and their derivatives. He has extensive experience in lineage specific differentiation of hESCs/iPSCs toward mesoderm cells (endothelial cells, smooth muscle cells, hematopoietic stem cells, megakaryocytes/platelets, erythrocytes, myeloid cells, and mesenchymal stem cells) and retinal cells (retinal ganglion cells, photoreceptors and corneal endothelial cells). The goal of his research is to generate hESC/iPSC-derived products for the treatment of human diseases. He has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials.

Research Interest

 Cell and Gene Engineering, Biotechnology